Associated tags: Patient, Stock exchange, Motherboard, CMS, Hospital, Safety, Pharmaceutical industry, Incidence, Tablet
Locations: SHENZHEN, CHINA, CN, HONG KONG, TAIWAN, MACAU, JAPAN, UNITED STATES
Epilepsy,
Seizure,
Consciousness,
Status epilepticus,
CMS,
Vitamin E,
Benzodiazepine,
Marketing,
Abbreviated New Drug Application,
Diazepam,
Clinical trial,
New Drug Application,
NDA,
Quality of life,
Absorption,
National Association Medical Staff Services,
Incidence,
Protein,
Patient,
Nasal mucosa,
Peptide,
National Medical Products Administration,
Ecosystem,
NMPA,
Caregiver,
Pharmaceutical industry,
Fine chemical CMS is pleased to announce the NDA of the first Diazepam Nasal Spray has been approved for marketing in China.
Key Points:
- CMS is pleased to announce the NDA of the first Diazepam Nasal Spray has been approved for marketing in China.
- The Product is the first diazepam nasal spray in China, and it is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e.
- The Product is a proprietary formulation of diazepam administered through the nasal mucosa, and has high bioavailability, outstanding absorbability, tolerance and reliability.
- Diazepam Nasal Spray is CMS's third innovative drug approved for marketing in China this year, following the approval of Methotrexate Injection and Tildrakizumab Injection.
The Spring Festival,
Maintenance,
CMS,
Marketing,
New Drug Application,
NDA,
Psoriasis,
Spring Festival,
Light,
Incidence,
Patient,
Autoimmune disease,
National Medical Products Administration,
PASI,
Chemokine,
Polidocanol,
NMPA,
Safety,
Vaccine,
Pharmaceutical industry This is CMS’s second innovative drug approved for marketing in China this year following the approval of Methotrexate Injection.
Key Points:
- This is CMS’s second innovative drug approved for marketing in China this year following the approval of Methotrexate Injection.
- ILUMETRI is CMS’s second innovative drug approved to be marketed in China in 2023, following the recent approval of Methotrexate Injection.
- ILUMETRI has been approved for marketing in the Hong Kong Special Administrative Region of China in April 2022.
- Tildrakizumab Injection has also been approved for marketing in the U.S., EU, Japan, UK, Switzerland, Canada, Australia and other countries/regions.
Retrieved on:
Wednesday, December 21, 2022
Ethereum,
FTX,
DAO,
CJ,
VCS,
Sale,
IDO,
Life,
Marketing,
Mechanics,
Video game,
Cryptocurrency As Chain Joes, players will combine their strength and fight against all the real enemies in a new and engaging mobile game.
Key Points:
- As Chain Joes, players will combine their strength and fight against all the real enemies in a new and engaging mobile game.
- Chain Joes offers players the opportunity to destroy, dismantle, and decimate the spammers, scammers, and hackers, preventing WEB3 from evolving into the magnificent resource the world needs.
- Chain Joes is a project built by gamers for gamers with support from blockchain professionals, marketing professionals, gaming professionals, and VCs.
- Join the Chain Joes whitelist today will grant EXCLUSIVE access to join the private sale starting after on the 26th of December.
Retrieved on:
Tuesday, December 6, 2022
Cream,
Janus,
Woman,
JAK,
Sclerotherapy,
Quality of life,
AD,
Incidence,
Partnership,
Atopic dermatitis,
Heredity,
Autoimmune disease,
Marketing,
FDA,
Safety,
Vitiligo,
CMS,
Skin,
Tablet,
Dermatology,
PD-1,
Neck,
TCS,
Face,
Plasma protein binding,
Territory,
Conditional sentence,
Patient,
Report,
Alopecia areata,
Prejudice,
Varicose veins,
Disease,
Ruxolitinib,
Patent,
FGFR1,
Janus kinase 1,
Week,
TCI,
Pharmaceutical industry,
Fine chemical,
Lancet,
Incyte,
Novartis,
Lilly Ruxolitinib Cream is the only topical JAK inhibitor and the first vitiligo repigmentation drug approved by the U.S. FDA.
Key Points:
- Ruxolitinib Cream is the only topical JAK inhibitor and the first vitiligo repigmentation drug approved by the U.S. FDA.
- Through this transaction, CMS once again brings a novel treatment option for patients with unmet medical needs.
- The product was approved by the FDA in July 2022 for the topical non-segmental vitiligo patients.
- In July this year, Ruxolitinib Cream became the first and only drug approved by the U.S. FDA for vitiligo patients repigmentation.
Retrieved on:
Friday, November 18, 2022
The Marketing Practice,
CMS,
Management,
Home Office hostile environment policy,
ESG,
Social,
Occupational safety and health,
Patient,
Social Security Government Pension Offset,
Human rights,
Sustainable development,
Marketing,
S&P Global,
Information,
Social responsibility,
Risk management,
Health care SHENZHEN, CHINA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Recently, the S&P Global Corporate Sustainability Assessment (S&P Global CSA) released the 2022 Environmental, Social and Governance (ESG) scores for China Medical System Holdings Limited ("CMS" or the "Group").
Key Points:
- SHENZHEN, CHINA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Recently, the S&P Global Corporate Sustainability Assessment (S&P Global CSA) released the 2022 Environmental, Social and Governance (ESG) scores for China Medical System Holdings Limited ("CMS" or the "Group").
- CMS achieved a significant improvement with a score of 53 in 2022 from 36 in 2021, surpassing 92% of the global peers and being significantly ahead of the industry average.
- S&P Global CSA is the global leading assessment tool of corporate sustainability practices initiated by S&P Global.
- S&P Global CSA has been regarded, by stakeholders, as one of the most important references for making business or investment decisions.
